
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IP3R-III CRISPR Activation Plasmid (m) | sc-421194-ACT | 20 µg | $397.00 |
Itpr3 encodes the mouse inositol 1,4,5-trisphosphate receptor type 3 (IP3R-III), an endoplasmic reticulum Ca²⁺ release channel that couples GPCR/PLC signaling to intracellular calcium oscillations. IP3R-III-mediated Ca²⁺ flux regulates secretion, epithelial polarity, mitochondrial metabolism, and apoptotic signaling, integrating calcium dynamics with MAPK and NFAT-dependent transcriptional programs. Altered IP3R-III expression or calcium homeostasis has been linked to dysregulated epithelial differentiation and stress responses, making Itpr3 a useful node for studying calcium signaling circuitry relevant to inflammation and tumor-associated phenotypes.
IP3R-III CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Itpr3 expression without altering the underlying DNA sequence.
IP3R-III CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Itpr3 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Itpr3 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous IP3R-III expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Itpr3 locus and enabling the study of IP3R-III-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of IP3R-III pathway restoration in tumor cells with silenced or reduced Itpr3 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.